Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes, and other diseases. Currently, most approved cell-based therapies use an individual’s own cells, but the next generation of these therapies will be made from donor-derived blood and tissue. That raises critical questions about how to recruit, retain, and fairly compensate donors while ensuring their safety throughout the donation process. Read Priya Baraniak’s opinion on what should be considered by regulators, suppliers, and researchers across the industry. Read full article
Meram received her master’s degree in biomedical sciences from Barry University and bachelor’s in Biology from Palm Beach Atlantic University.
Before her position at OrganaBio, Meram conducted research at Larkin University where she worked on assessing the impact of Hurricane Maria on respiratory diseases in Puerto Rico, which provided her with insight into research investigation and analysis along with generation of grant documentation.